Geron traded at $1.88 this Friday February 20th, decreasing $0.04 or 2.08 percent since the previous trading session. Looking back, over the last four weeks, Geron lost 40.30 percent. Over the last 12 months, its price fell by 26.85 percent. Looking ahead, we forecast Geron to be priced at 1.82 by the end of this quarter and at 1.66 in one year, according to Trading Economics global macro models projections and analysts expectations.
Geron Corporation is a late-stage clinical biopharmaceutical company, which is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).